Phase 1 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with advanced or metastatic cancer through a tissue sample test (currently, only colorectal cancer patients are being enrolled).
- People who are 18 years of age or older and are willing and able to give their consent to participate.
- People who have cancer that can be measured on scans or other tests.
- People who are relatively active and able to carry out daily activities (rated 0 or 1 on a standard health scale used by doctors), with a life expectancy of at least 12 weeks.
Who may not be able to join:
- People who have a history of allergic reactions or serious reactions to any of the medicines used in this trial, including any antibody-based treatments.
- People who have taken part in another clinical trial involving an experimental treatment within the past 28 days before starting this trial, or who plan to do so during the study.
- People who are currently receiving high doses of steroid medicines or any other medicines that suppress the immune system.
- People who have a history of severe autoimmune disease (a condition where the immune system attacks the body's own tissues).
- People who have another serious illness that is not well controlled, or another type of cancer that currently requires treatment.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 888-585-2990
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
1. To determine the anti-tumor activity of TTX-080 by objective response rate [complete response + partial response) for each tumor arm per RECIST 1.1
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.